Kadsurenone | CAS#95851-37-9 | platelet-activating factor receptor antagonist

MedKoo Cat#: 462095 | Name: Kadsurenone

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Kadsurenone is a platelet-activating factor receptor antagonist from Chinese herbal plant, haifenteng. It is a useful and promising treatment strategy for breast cancer bone metastases by blocking the PAF/PTAFR signaling pathway.

Chemical Structure

Kadsurenone

CAS#95851-37-9

Theoretical Analysis

MedKoo Cat#: 462095

Name: Kadsurenone

CAS#: 95851-37-9

Chemical Formula: C21H24O5

Exact Mass: 356.1624

Molecular Weight: 356.42

Elemental Analysis: C, 70.77; H, 6.79; O, 22.44

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Kadsurenone; Denudatin B

IUPAC/Chemical Name

6(2H)-Benzofuranone, 2-(3,4-dimethoxyphenyl)-3,3a-dihydro-3a-methoxy-3-methyl-5-(2-propenyl)-, (2S-(2alpha,3beta,3aalpha))-

InChi Key

VDYACOATPFOZIO-UBWHGVKJSA-N

InChi Code

InChI=1S/C21H24O5/c1-6-7-15-12-21(25-5)13(2)20(26-19(21)11-16(15)22)14-8-9-17(23-3)18(10-14)24-4/h6,8-13,20H,1,7H2,2-5H3/t13-,20+,21+/m1/s1

SMILES Code

O=C1C(CC=C)=C[C@]2(OC)[C@H](C)[C@@H](C3=CC=C(OC)C(OC)=C3)OC2=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 356.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kadsurenone distinguishes between different platelet activating factor receptor subtypes on macrophages and polymorphonuclear leucocytes. G. Lambrecht, M. J. Parnham Br J Pharmacol. 1986 Feb; 87(2): 287–289. doi: 10.1111/j.1476-5381.1986.tb10816.x PMCID: PMC1916546 2: Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects. T Y Shen, S B Hwang, M N Chang, T W Doebber, M H Lam, M S Wu, X Wang, G Q Han, R Z Li Proc Natl Acad Sci U S A. 1985 Feb; 82(3): 672–676. doi: 10.1073/pnas.82.3.672 PMCID: PMC397107 3: Antagonism of platelet activating factor-induced chemiluminescence in guinea-pig peritoneal macrophages in differing states of activation. M. J. Parnham, C. Bittner, G. Lambrecht Br J Pharmacol. 1989 Oct; 98(2): 574–580. doi: 10.1111/j.1476 5381.1989.tb12631.x PMCID: PMC1854744 4: Enhanced human monocyte cytotoxicity by platelet-activating factor. F H Valone, R Philip, R J Debs Immunology. 1988 Aug; 64(4): 715–718. PMCID: PMC1384996 5: Kadsurenone is a useful and promising treatment strategy for breast cancer bone metastases by blocking the PAF/PTAFR signaling pathwayTianhui Hou, Yan Lou, Shichang Li, Chenglong Zhao, Yingzheng Ji, Dongsheng Wang, Liang Tang, Ming Zhou, Wei Xu, Ming Qian, Zhipeng Wu, Jian Zhao, Haifeng Wei, Zhenxi Li, Jianru Xiao Oncol Lett. 2018 Aug; 16(2): 2255–2262. Published online 2018 Jun 8. doi: 10.3892/ol.2018.8935 PMCID: PMC6036417 6: A Network Pharmacology-Based Strategy For Predicting Active Ingredients And Potential Targets Of LiuWei DiHuang Pill In Treating Type 2 Diabetes Mellitus Dan He, Jian-Hua Huang, Zhe-Yu Zhang, Qing Du, Wei-Jun Peng, Rong Yu, Si-Fang Zhang, Shui-Han Zhang, Yu-Hui Qin Drug Des Devel Ther. 2019; 13: 3989–4005. Published online 2019 Nov 28. doi: 10.2147/DDDT.S216644Correction in: Drug Des Devel Ther. 2020; 14: 949. PMCID: PMC6890936 7: Antagonism of Paf-induced oedema formation in rabbit skin: a comparison of different antagonists. P. G. Hellewell, T. J. Williams Br J Pharmacol. 1989 May; 97(1): 171–180. doi: 10.1111/j.1476-5381.1989.tb11939.x PMCID: PMC1854485 8: The inflammatory response of rabbit skin to topical arachidonic acid and its pharmacological modulation. D. Aked, S. J. Foster, A. Howarth, M. E. McCormick, H. C. Potts Br J Pharmacol. 1986 Oct; 89(2): 431–438. doi: 10.1111/j.1476-5381.1986.tb10277.x PMCID: PMC1917011 9: Stimulation of tumour necrosis factor release by cytotoxic analogues of platelet-activating factor. F H Valone, N M Ruis Immunology. 1992 May; 76(1): 24–29. PMCID: PMC1421731 10: Oxetane Synthesis through the Paternò-Büchi Reaction Maurizio D’Auria, Rocco Racioppi Molecules. 2013 Sep; 18(9): 11384 11428. Published online 2013 Sep 16. doi: 10.3390/molecules180911384 PMCID: PMC6269742